Sunitinib malate for the treatment of solid tumours: A review of current clinical data

Expert Opinion on Investigational Drugs

Volumn 15, Issue 5, 2006, Pages 553-561

  Motzer, Robert J ^a   Hoosen, Sakina ^b   Bello, Carlo L ^b   Christensen, James G ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Antiangiogenic; Antitumour; GIST; Inhibitor; Multitargeted tyrosine kinase; RCC; Solid tumours; SU11248; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 2; KETOCONAZOLE; OCTREOTIDE; PLACEBO; PROTEIN TYROSINE KINASE; RIFAMPICIN; SUNITINIB; TAXANE DERIVATIVE; TRIACYLGLYCEROL LIPASE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE MODEL; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; MOUTH PAIN; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; REVIEW; SARCOMA; SKIN DISCOLORATION; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; NEOPLASMS; PYRROLES;

EID: 33646448005     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.5.553     Document Type: Review

References (56)

1. KRAUSE DS, VAN ETTEN RA: Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. (2005) 353(2):172-187.
2. SCHLESSINGER J: Signal transduction. Autoinhibition control. Science (2003) 300(5620):750-752.
3. MECHTERSHEIMER G, EGERER G, HENSEL M et al.: Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. (2004) 444(2):108-118.
4. RABEN D, HELFRICH B, BUNN PA Jr: Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(Suppl. 2):27-38.
5. VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2(7):489-501.
6. ABRAMS TJ, MURRAY LJ, PESENTI E et al.: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. (2003) 2(10):1011-1021.
7. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9(1):327-337.
8. O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101(9):3597-3605.
9. PFIZER, INC.: Data on file, New York, NY, USA (2006) (Unpublished data).
10. MURRAY LJ, ABRAMS TJ, LONG KR et al.: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis (2003) 20(8):757-766.
11. FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
12. HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23(5):1011-1027.
13. PIETRAS K, SJOBLOM T, RUBIN K, HELDIN CH, OSTMAN A: PDGF receptors as cancer drug targets. Cancer Cell (2003) 3(5):439-443.
14. BERGERS G, SONG S: The role of pericytes in blood-vessel formation and maintenance. Neuro-oncol. (2005) 7(4):452-464.
15. BERGERS G, SONG S, MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. (2003) 111(9):1287-1295.
16. ERBER R, THURNHER A, KATSEN AD et al.: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. (2004) 18(2):338-340.
17. CORLESS CL, FLETCHER JA, HEINRICH MC: Biology of gastrointestinal stromal tumors. J. Clin. Oncol. (2004) 22(18):3813-3825.
18. HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21(23):4342-4349.
19. STIREWALT DL, RADICH JP: The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer (2003) 3(9):650-665.
20. JHIANG SM: The RET proto-oncogene in human cancers. Oncogene (2000) 19(49):5590-5597.
21. KARPANEN T, EGEBLAD M, KARKKAINEN MJ et al.: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. (2001) 61(5):1786-1790.
22. SAPI E: The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp. Biol. Med. (Maywood) (2004) 229(1):1-11.
23. SAKAMOTO JM: SU-11248 Sugen. Curr. Opin. Investig. Drugs (2004) 5(12):1329-1339.
24. ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2(5):471-478.
25. SCHUENEMAN AJ, HIMMELFARB E, GENG L et al.: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. (2003) 63(14):4009-4016.
26. FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
27. MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
28. HOUK B, GARRETT M, BELLO C, POLAND B, WAGG J, GAO Y: Population pharmacokinetics (PK) of sunitinib malate (SU11248) and its primary metabolite (SU12662) in oncology patients and healthy volunteers. Clin. Cancer Res. (2005) 11 (Suppl. 24):9074s-9075s (Abstract B9171).
29. WASHINGTON C, ELI M, BELLO C et al.: The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in caucasian and Asian healthy subjects. Proc. Am. Soc. Clin. Oncol. (2003) 22:138s (Abstract 553).
30. BELLO C, SHERMAN L, ZHOU J et al.: Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a Phase I study in healthy subjects. Anticancer Drugs (2006) 17(3):353-358.
31. JANZEN NK, KIM HL, FIGLIN RA, BELLDEGRUN AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. (2003) 30(4):843-852.
32. LAM JS, LEPPERT JT, BELLDEGRUN AS, FIGLIN RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. (2005) 23(3):202-212.
33. CHOW WH, DEVESA SS, WARREN JL, FRAUMENI JF Jr: Rising incidence of renal cell cancer in the United States. J. Am. Med. Assoc. (1999) 281(17):1628-1631.
34. LILLEBY W, FOSSA SD: Chemotherapy in metastatic renal cell cancer. World J. Urol. (2005) 23(3):175-179.
35. ROHRMANN K, STAEHLER M, HASEKE N, BACHMANN A, STIEF CG, SIEBELS M: Immunotherapy in metastatic renal cell carcinoma. World J. Urol. (2005) 23(3):196-201.
36. PANTUCK AJ, ZENG G, BELLDEGRUN AS, FIGLIN RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. (2003) 9(13):4641-4652.
37. RINI BI, SMALL EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. (2005) 23(5):1028-1043.
38. MOTZER R, RINI B, MICHAELSON M et al.: Sunitinib malate (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from Phase II trials. Eur. J. Cancer Suppl. (2005) 3(2):227 (Abstract 797).
39. DEPRIMO SE, BELLO CL, SMERAGLIA J et al.: Soluble protein biomarkers of pharmacodynamic activity of the multitargeted tyrosine kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma. 96th Annual Meeting of the American Association for Cancer Research, Anaheim, USA (16 - 20 April 2005) (Abstract 464).
40. MOTZER RJ, BACIK J, MURPHY BA, RUSSO P, MAZUMDAR M: Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. (2002) 20(1):289-296.
41. ESCUDIER B, CHEVREAU C, LASSET C et al.: Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J. Clin. Oncol. (1999) 17(7):2039-2043.
42. CORLESS CL, SCHROEDER A, GRIFFITH D et al.: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. (2005) 23(23):5357-5364.
43. BLANKE CD, CORLESS CL: State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. (2005) 23(3):274-280.
44. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347(7):472-480.
45. VAN GLABBEKE M, VERWEIJ J, CASALI PG et al.: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. (2005) 23(24):5795-5804.
46. MORGAN JA, DEMETRI GD, FLETCHER JA et al.: Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinb malate (SU11248). European Cancer Conference (ECCO 13), Paris, France 30 October - 3 November 2005. Eur. J. Cancer Suppl. (2005) 3(2):421 (Abstract 1456).
47. DEMETRI GD, VAN OOSTEROM A, GARRETT C et al.: Sunitinib malate (SU11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: update of a Phase III trial. Eur. J. Cancer Suppl. (2005) 3(2):203 (Abstract 716).
48. PRICE DJ, MIRALEM T, JIANG S, STEINBERG R, AVRAHAM H: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. (2001) 12(3):129-135.
49. DE JONG JS, VAN DIEST PJ, VAN DER VALK P, BAAK JP: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J. Pathol. (1998) 184(1):44-52.
50. TERRIS B, SCOAZEC JY, RUBBIA L et al.: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 32(2):133-138.
51. CHRISTOFORI G, NAIK P, HANAHAN D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol. (1995) 9(12):1760-1770.
52. CHAUDHRY A, FUNA K, OBERG K: Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. (1993) 32(2):107-114.
53. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
54. HEINRICH MC, CORLESS CL: Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J. Surg. Oncol. (2005) 90(3):195-207 (Discussion 207).
55. PRAKASH S, SARRAN L, SOCCI N et al.: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. (2005) 27(4):179-187.
56. PRICE VE, ZIELENSKA M, CHILTON-MacNEILL S, SMITH CR, PAPPO AS: Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr. Blood Cancer (2005) 45(1):20-24.